What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.
Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.
Topic: Microplastics regulation in European Union
Date of publication: 30/08/2022 (draft)
On August 30, 2022, the European Commission released a draft proposal to restrict intentionally added microplastics. The restriction would comprise synthetic polymer microparticles below 5 mm and fiber-like particles below 15 mm that are used in products on intention and may result in environmental release.
Topic: Green Dot labelling in Spain
Date of publication: 27/12/2022
Date of application: 01/01/2025
Spanish Royal Decree 1055/2022 will apply as of January 1, 2025, introducing several new requirements on packaging.
Ingredients: BENZOPHENONE-3, OCTOCRYLENE
Date of publication: 07/07/2022
Date of application: 28/01/2023 (placing on the market); 28/07/2023 (sell-off)
Regulation (EU) 2022/1176 amends Regulation (EC) No 1223/2009, restricting the use of Benzophenone-3 and Octocrylene as UV filters in cosmetic products.
Ingredients: ALUMINUM COMPOUNDS
Date of publication: 02/02/2023
On February 2, 2023, the Scientific Committee on Consumer Safety (SCCS) published its final opinion on the use of aluminum in cosmetic products.
Topic: Glossary of common ingredient names, INCI list
Date of publication: 31/03/2022
The European Commission has published the Commission Implementing Decision (EU) 2022/677, which updates the Glossary of common ingredient names for use in the labelling of cosmetic products, applicable from 29 April 2023.
Ingredients: KARANAL
Date of application: 27/08/2023
Karanal has been added to the SVHC's list. The deadline for placing cosmetic products containing Karanal on the European Union market will be until August 27, 2023.
Ingredients: COSMETIC FRAGRANCES and AROMATIC COMPOSITIONS
Date of publication: Expected in June 2023
IFRA is preparing the 51st Amendment to its standards. The proposed amendment is open for consultation until February 28, 2023, in order to give the industry the opportunity to submit its comments. Official notification of the 51st Amendment is expected in June 2023.
Ingredients: BHT, ACID YELLOW 3, HOMOSALATE, HAA299 and RESORCINOL
Date of publication: 11/11/2022
Date of application: 01/07/2023
Commission Regulation (EU) 2022/2195 of November 2022 amends Regulation (EC) No 1223/2009, restricting the use of BHT, Acid Yellow 3, Homosalate, HAA299 and Resorcinol, in cosmetic products.
Ingredient: CYCLAMEN ALDEHYDE
Date of publication: 8 June 2026
The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.
Topic: OMNIBUS ACT IX - COSMETICS REGULATION
Date of publication: 28 July 2026
The European Commission notified the WTO about the draft Omnibus Act IX, proposing amendments to Annexes II, III, and V of the EU Cosmetics Regulation.
Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS
Date of publication: 13 January 2026
The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).
Ingredient: TALC
Date of publication: January 2026
The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.
Four EUDAMED modules have been mandatory since 28 May 2026. Devices already on the market have until 27 November 2026. Who registers what, and what changed in Portugal.
From 25 February 2027, notified bodies under the MDR and IVDR must quote on defined information, keep to maximum timelines and publish their performance. What it changes for manufacturers.
Whether software is a medical device depends on what you say it is for, not on the code. The qualification test under the MDR and IVDR, updated for 2025 guidance.
Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.
One email when an area publishes, in the language you choose. Nothing else.
